[June 20, 2016] |
|
Zika Virus Opportunities And Threats - Research and Markets
Research and Markets has announced the addition of the "Anti-Infective
Drug News Issue 339" report to their offering.
As well as a number of smaller developers looking to carve a niche for
themselves, we would expect the most prominent vaccine developers to
focus on Zika vaccine research. The travel vaccine market would provide
an element of profitability, but regional brand establishment will be a
more significant draw. The lack of prophylactic options should not
immediately impact Brazil's tourist industry, but this year's big events
will act as a test case, guiding future travel advice.
Key Topics Covered:
-
Zika Virus Opportunities And Threats
-
FDA Accepts Teflaro sNDA For Filing
-
MGB Biopharma/UoS To Co-Develop Novel MGB Anti-Infectives
-
Telephus Secures Australian Patent Covering Therapeutic Abs For
Staphylococcus Infections
-
Bavarian Nordic Enters Research Collaboration To Develop MRSA Vacine
-
Allergan/AstraZeneca Collaborate To Develop ATM-AVI Antibiotic
-
Theravance Launches Vibativ In Canada
-
Reaching Stakeholder Consensus Key To Tackling AMR Threat
-
VAXEM Hib Approved In Japan
-
FDA Approves Updated Dalvance Dosing
-
Cidara's CD101 IV Gains FDA ODD For Candidaemia/Invasive Candidiasis
-
SCYNEXIS' Antifungal Receives FDA Fast Track and QIDP Designations
-
Aurobindo Gains FDA Voriconazole Approval
-
FDA Approves Harvoni For HCV Patients With Advanced Liver Disease
-
Health Canada Accepts Sitavig NDA For Review
-
Protein Sciences/UNIGEN To Source (News - Alert) Flublok From Japan
-
FDA Approves Expanded Use Of Daklinza
-
Valneva/GSK Enter R&D Collaboration For EB66 Cell Line
-
Merck's Zepatier Approved In Canada
-
Sanofi Pasteur Targeting Zika Vaccine
-
GeoVax To Develop Zika Vaccine
-
GSK Seeks US Approval For Expanded Use Of FluLaval Quadrivalent
-
NewLink Genetics To Develop New Zika Treatment Options
-
UniSA Partners With Biotech Company To Develop Zika Vaccine
-
FDA Approves Merck's Fixed-Dose HCV Regimen
-
EC Approves Expanded Use Of Daklinza
-
Region To Remain Vulnerable To Zika
-
Zika Outbreak Poses Diagnostic Opportunity
-
Gilead In Strong Position To Counter TAF Lawsuit
-
Gilead To Target (News - Alert) Transformational Opportunities
-
Dynamics Within Industry-Academia Partnerships Changing
For more information visit http://www.researchandmarkets.com/research/xdqgbf/antiinfective
View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005632/en/
[ Back To TMCnet.com's Homepage ]
|